⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
Francia amplía el acceso nacional a la AAC para el botensilimab + balstilimab de Agenus para el cáncer de ovario y los sarcomas de tejidos blandos
businesswire.com
AGEN
França amplia o acesso nacional via AAC ao Botensilimabe + Balstilimabe da Agenus para câncer de ovário e sarcomas de tecidos moles
businesswire.com
AGEN
フランス、卵巣がんおよび軟部肉腫を対象に、アジーナスの「ボテンシリマブ＋バルスチリマブ」について国家レベルのAACアクセスを拡大
businesswire.com
AGEN
Frankreich erweitert den nationalen AAC-Zugang für Botensilimab und Balstilimab von Agenus zur Behandlung von Eierstockkrebs und Weichteilsarkomen
businesswire.com
AGEN
Frankrijk breidt nationale AAC-toegang uit voor Agenus' botensilimab + balstilimab voor eierstokkanker en wekedelensarcomen
businesswire.com
AGEN
法國擴大Agenus用於治療卵巢癌和軟組織肉瘤的Botensilimab + Balstilimab組合療法的國家同情用藥授權範圍
businesswire.com
AGEN
法国扩大Agenus用于治疗卵巢癌和软组织肉瘤的Botensilimab + Balstilimab组合疗法的国家同情用药授权范围
businesswire.com
AGEN
La Francia espande l'accesso nazionale all'AAC per botensilimab + balstilimab di Agenus per il carcinoma ovarico e i sarcomi dei tessuti molli
businesswire.com
AGEN
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
businesswire.com
AGEN
NanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug Portfolio
prnewswire.com
AGEN